Rytelo
Geron Corporation Loses Chief Commercial Officer Following FDA Approval of RYTELO
Geron Corporation, Chief Commercial Officer, FDA Approval, RYTELO, Blood Cancer Treatment
Geron’s Rytelo Receives FDA Approval for Lower-Risk Myelodysplastic Syndromes Treatment
Geron, Rytelo, FDA Approval, Blood Cancer, Myelodysplastic Syndromes, Telomerase Inhibitor, Imetelstat